SavedAdd your journal

Journals / Androloji Bülteni / 2017 / Cilt: 19 - Sayı: 4

Testosterone replacement and its cardiovascular side effects

Testosteron replasmanı ve kardiyovasküler yan etkileri

Ali ATAN
Süleyman YEŞİL
Fazlı POLAT
Pages
127–130
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we present the effects of T on the cardiovascular system by reviewing the current international literature

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Testosterone (T) is a hormone produced by the connection between the hypothalamus, pituitary and testis.
📊
Key Findings & Data:It is known that T has positive effects on many organs and systems.
💡
Conclusion & Impact:In this review, we present the effects of T on the cardiovascular system by reviewing the current international literature
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Testosterone (T) is a hormone produced by the connection between the hypothalamus, pituitary and testis. It is known that T has positive effects on many organs and systems. In spite of these beneficial effects, there are concerns about some adverse effects on the prostate and cardiovascular system. The association of T with prostate cancer has been intensively studied in recent years and it has been shown that endogenous T levels and T-replacement therapy have no effect on prostate cancer formation. In this review, we present the effects of T on the cardiovascular system by reviewing the current international literature

Özet

Testosteron (T), hipotalamus, hipofiz ve testis arasındaki bağlantı sonucu üretilen bir hormondur. T'un pek çok organ ve sistem üzerinde olumlu etkiler gösterdiği bilinmektedir. Bu faydalı etkilerine karşın, prostat ve kardiyovasküler sistem üzerinde bazı olumsuz etkiler oluşturduğu ile ilgili endişeler de vardır. T'un prostat kanseri ile olan ilişkisi son yıllarda yoğun olarak çalışılmış ve endojen T düzeyi ile T replasman tedavisinin prostat kanseri oluşumunda bir etkisinin olmadığı gösterilmiştir. Bu derlemede, mevcut uluslararası literatür gözden geçirilerek, T'un kardiyovasküler sistem üzerindeki etkileri sunulmaktadır

🔖

Cite This Article

ATAN, A., YEŞİL, S., POLAT, F. (2017). Testosterone replacement and its cardiovascular side effects. Androloji Bülteni, Cilt: 19 - Sayı: 4, 127–130. https://ajindex.com/articles/148485

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd. Testosterone and Cardiovascular Disease. J Am Coll Cardiol 2016
  2. 545–57. doi: 10.1016/j.jacc.2015.12.005 2. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005
  3. 833–76. doi: 10.1210/er.2004-0013 3. Mulligan T, Frick M, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006
  4. 762–9. doi: 10.1111/j.1742- 1241.2006.00992.x 4. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010
  5. 1186–92. doi: 10.2337/dc09-1649 5. Morgentaler A. Controversies and Advances with Testosterone Therapy: A 40-Year Perspective. Urology 2016
  6. 27–32. doi: 10.1016/j.urology.2015.11.034 6. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010
  7. 109–22. doi: 10.1056/ NEJMoa1000485 7. Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013
  8. 1829–36. doi: 10.1001/ jama.2013.280386 8. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and metaanalysis of placebo-controlled randomized trials. BMC Med 2013
  9. doi: 10.1186/1741-7015-11-108 9. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014
  10. e85805. doi: 10.1371/journal.pone.0085805 10. Layton JB, Meier CR, Sharpless JL, Stürmer T, Jick SS, Brookhart MA. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med 2015
  11. 1187–96. doi: 10.1001/ jamainternmed.2015.1573 11. Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! J Sex Med 2014
  12. 624–9. doi: 10.1111/jsm.12464 12. Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. Aging Male 2014
  13. 63–5. doi: 10.3109/13685538.2014.913413 13. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc